BofA lowered the firm’s price target on AMN Healthcare (AMN) to $26 from $30 and keeps an Underperform rating on the shares. Q4 EBITDA beat expectations, but the next quarter’s core guidance is “well below expectations,” says the analyst, who cut the firm’s 2025 and 2026 EBITDA estimates to reflect the lower run-rate.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMN:
- AMN Healthcare price target lowered to $40 from $47 at Truist
- Cautious Outlook on AMN Healthcare Services Amid Lower Guidance and Contract Labor Challenges
- AMN Healthcare Reports 2024 Financial Results and Outlook
- Closing Bell Movers: Booking gains 3%, Akamai down 8% on earnings
- AMN Healthcare sees Q1 revenue $660M – $680M , consensus $657.8M